Chris Bohn had four goals and two assists, and Mike Arcure had three goals to lead Abington Heights to a 17-3 win over North ...

FN rounds up some of the standout shoe looks from weekend one of the star-studded festival.

Novo Nordisk has reported the first mid-stage clinical data with its triple G agonist for diabetes in China, as it starts an international trials programme. The drug candidate, UBT251, acts on GLP-1, ...

Novo Nordisk and its Chinese partner have reported another midphase win for their triple-G candidate, sharing diabetes data to add to the momentum generated by an obesity readout. But, while the data ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Diabetes patients taking ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Regulators are trying to push drug development into a post-animal testing era. Meanwhile, a Jennifer Doudna-founded company ...

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Here's the revised description without any links: Sean Zittel of Tha Boxing Voice interviews the legendary Teddy Atlas on his thoughts about "Triple G" Gennady Golovkin, his reputation, and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in type 2 diabetes (T2D) to go with its earlier encouraging data as a weight-loss therapy. The GIP, GLP-1 and glucagon agonist ...

UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk In a phase 2 trial in Chinese people with type 2 ...